NCT02000440 · Interventional trial
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Overall registry status Completed
Phase 2
Conditions Glomerulosclerosis, Focal Segmental
Delaware Valley sites
- GSK Investigational Site · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory